PrimaryBid SA was pleased to support Biophytis, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with ageing, on its recent €2.3m capital raise.
This transaction marked the first time that PrimaryBid has helped raise money for a dual-listed issuer in Europe with Biophytis listed on Euronext and Nasdaq (Nasdaq: BPTS, Euronext Growth Paris: ALBPS).
Stanislas Veillet, CEO of Biophytis stated: “On behalf of Biophytis team, I would like to warmly thank all of the professional investors, historical Company’s investors, for their support, and retail investors through PrimaryBid who participated in this fundraising. This transaction will allow us to file regulatory applications for Marketing Authorisation in Europe and the United States for Sarconeos (BIO101) in the treatment of severe forms of COVID-19”.
The transaction saw strong demand from retail investors on the PrimaryBid platform.
This French deal was only available to investors in France. Investing in securities involves risk.
Read more about the deal here.